Drugs / rDEN2/4delta30(ME)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00920517 Comparator | Jan 2009 → Jan 2010 | dengue disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rDEN2/4delta30(ME) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00920517 ↗ |
| Modality | Vaccine | “The rDEN2/4delta30(ME) vaccine is a live attenuated dengue virus vaccine” NCT00920517 ↗ |